Myovant Sciences to Host Second Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on October 26, 2021
Myovant Sciences (NYSE: MYOV) announced a webcast and conference call on October 26, 2021, at 8:30 a.m. ET to discuss its corporate updates and second fiscal quarter financial results for the period ending September 30, 2021. Investors can access the live webcast on Myovant's investor relations website. The company has two FDA-approved products: ORGOVYX for advanced prostate cancer and MYFEMBREE for heavy menstrual bleeding. A supplemental New Drug Application for endometriosis management is currently under FDA review.
- Announcement of a webcast for financial results may increase transparency with investors.
- Two FDA-approved products could enhance revenue prospects.
- None.
BASEL, Switzerland, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter 2021, ended September 30, 2021. The webcast and conference call will be held at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on October 26, 2021.
Investors and the general public may access a live webcast of the call by visiting the investor relations page of Myovant’s website at investors.myovant.com. Institutional investors and analysts may also participate in the conference call by dialing 1-800-532-3746 in the U.S. or +1-470-495-9166 from outside the U.S.
A replay of the webcast, along with the earnings press release and presentation materials, will be archived on Myovant’s investor relations website.
About Myovant Sciences
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Founded in 2016, we have two FDA-approved products. ORGOVYX® (relugolix) was approved by the U.S. Food and Drug Administration in 2020 as the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and relugolix is also under regulatory review in Europe for men with advanced prostate cancer. Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) was approved in 2021 in the U.S. as MYFEMBREE® as the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, and by the European Commission as RYEQO® for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. We have filed a supplemental New Drug Application (sNDA) for the management of moderate to severe pain associated with endometriosis, which was accepted for review by the FDA in September 2021. The therapy is also being assessed for the prevention of pregnancy. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn.
Investor Contact:
Ryan Crowe
Vice President, Investor Relations
+1 (650) 781-9106
investors@myovant.com
Media Contact:
Albert Liao
Director, Corporate Communications
+1 (650) 410-3055
media@myovant.com
FAQ
What financial results will Myovant Sciences discuss on October 26, 2021?
How can I access the Myovant Sciences conference call?
What are the FDA-approved products of Myovant Sciences?
Is Myovant Sciences awaiting any FDA decisions?
